Hemicraniectomy for Malignant Middle Cerebral Artery Syndrome: A Review of Functional Outcomes in Two High-Volume Stroke Centers.
Hemicraniectomy for Malignant Middle Cerebral Artery Syndrome: A Review of Functional Outcomes in Two High-Volume Stroke Centers.
- 2018
BACKGROUND AND PURPOSE: Despite recent landmark randomized controlled trials showing significant benefits for hemicraniectomy (HCT) compared with medical therapy (MT) in patients with malignant middle cerebral artery infarction (MMCAI), HCT rates have not substantially increased in the United States. We sought to evaluate early outcomes in patients with MMCAI who were treated with HCT (cases) in comparison to patients treated with MT due to the perception of procedural futility by families (controls). CONCLUSIONS: HCT is a critical and effective therapy for patients with MMCAI but cannot provide a guarantee of functional recovery. Copyright Published by Elsevier Inc. METHODS: We retrospectively evaluated consecutive patients with acute MMCAI treated in 2 tertiary care centers during a 7-year period. Pretreatment National Institutes of Health Stroke Scale (NIHSS) and modified Rankin Scale (mRS) at 3 months were documented. Functional independence (FI) and survival without severe disability (SWSD) were defined as mRS of 0-2 and 0-4, respectively. RESULTS: A total of 66 patients (37 cases and 29 controls) fulfilled the study inclusion criteria (mean age 59+/-15 years, 52% men, median admission NIHSS score: 19 points [interquartile range : 16-22]). Cases were younger (51+/-11 versus 68+/-13 years; P<.001) and tended to have lower median admission NIHSS than controls (18 [IQR:16-20] versus 20 [IQR:18-23]; P=.072). The rates of FI and SWSD at 3 months were higher in cases than controls (16% versus 0% [P=.031] and 62% versus 0% [P<.001]), while 3-month mortality was lower (24% versus 77%; P<.001). Multivariable Cox regression analyses adjusting for potential confounders identified HCT as the most important predictor of lower risk of 3-month mortality (hazard ratio: .02, 95% confidence interval: .01-0.10; P<.001).
English
1052-3057
10.1016/j.jstrokecerebrovasdis.2018.04.031 [doi] S1052-3057(18)30207-6 [pii]
IN PROCESS -- NOT YET INDEXED
MedStar Washington Hospital Center
Neurology
Journal Article
BACKGROUND AND PURPOSE: Despite recent landmark randomized controlled trials showing significant benefits for hemicraniectomy (HCT) compared with medical therapy (MT) in patients with malignant middle cerebral artery infarction (MMCAI), HCT rates have not substantially increased in the United States. We sought to evaluate early outcomes in patients with MMCAI who were treated with HCT (cases) in comparison to patients treated with MT due to the perception of procedural futility by families (controls). CONCLUSIONS: HCT is a critical and effective therapy for patients with MMCAI but cannot provide a guarantee of functional recovery. Copyright Published by Elsevier Inc. METHODS: We retrospectively evaluated consecutive patients with acute MMCAI treated in 2 tertiary care centers during a 7-year period. Pretreatment National Institutes of Health Stroke Scale (NIHSS) and modified Rankin Scale (mRS) at 3 months were documented. Functional independence (FI) and survival without severe disability (SWSD) were defined as mRS of 0-2 and 0-4, respectively. RESULTS: A total of 66 patients (37 cases and 29 controls) fulfilled the study inclusion criteria (mean age 59+/-15 years, 52% men, median admission NIHSS score: 19 points [interquartile range : 16-22]). Cases were younger (51+/-11 versus 68+/-13 years; P<.001) and tended to have lower median admission NIHSS than controls (18 [IQR:16-20] versus 20 [IQR:18-23]; P=.072). The rates of FI and SWSD at 3 months were higher in cases than controls (16% versus 0% [P=.031] and 62% versus 0% [P<.001]), while 3-month mortality was lower (24% versus 77%; P<.001). Multivariable Cox regression analyses adjusting for potential confounders identified HCT as the most important predictor of lower risk of 3-month mortality (hazard ratio: .02, 95% confidence interval: .01-0.10; P<.001).
English
1052-3057
10.1016/j.jstrokecerebrovasdis.2018.04.031 [doi] S1052-3057(18)30207-6 [pii]
IN PROCESS -- NOT YET INDEXED
MedStar Washington Hospital Center
Neurology
Journal Article